•
Mar 31, 2023

Enfusion Q1 2023 Earnings Report

Enfusion grew revenue at double-digit rates and established itself as a partner of choice for investment managers.

Key Takeaways

Enfusion's Q1 2023 results showed double-digit revenue growth driven by new sales across products and services, with focused expense discipline maintaining a solid margin profile and strong cash conversion leading to positive adjusted free cash flow.

Enfusion's Q1 client wins demonstrate ongoing strength in conversions and further global expansion.

Signed a multi-billion-dollar venture capital fund replacing outdated technology with a cloud-native, end-to-end platform.

Signed a credit hedge fund through a relationship with Innocap Global Investment Management.

Signed a multi-billion dollar Chinese hedge fund based in Singapore, consolidating providers onto one platform.

Total Revenue
$41M
Previous year: $34.1M
+20.0%
EPS
$0.04
Previous year: -$0.1
-140.0%
Annual Recurring Revenue
$167M
Previous year: $138M
+21.4%
Gross Profit
$27.7M
Previous year: $23.2M
+19.5%
Cash and Equivalents
$54.6M
Previous year: $56.2M
-2.9%
Free Cash Flow
$924K
Previous year: -$7.27M
-112.7%
Total Assets
$121M
Previous year: $105M
+15.8%

Enfusion

Enfusion

Enfusion Revenue by Segment

Revenue & Expenses

Visualization of income flow from segment revenue to net income